HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evaluation of anthralin in the treatment of alopecia areata.

Abstract
Anthralin cream 0.5% to 1.0% was used to treat 68 patients with severe alopecia areata. Therapy was relatively well tolerated, although all patients experienced pruritus and local erythema and scaling. Cosmetic response was seen in 17 (25%) of the patients, and was maintained during therapy in 12 (71%) of the 17 cosmetic responders. For the patients treated with 0.5% anthralin, the mean time to response (44 of 66 patients) was 11 weeks; the mean time to cosmetic response (13 of 66 patients) was 23 weeks. Duration of the current episode of hair loss did not correlate with cosmetic response. Compared with other currently available topical treatments, anthralin appears to be a reasonable therapeutic option for severe alopecia areata.
AuthorsV C Fiedler-Weiss, C M Buys
JournalArchives of dermatology (Arch Dermatol) Vol. 123 Issue 11 Pg. 1491-3 (Nov 1987) ISSN: 0003-987X [Print] United States
PMID3314718 (Publication Type: Clinical Trial, Comparative Study, Journal Article)
Chemical References
  • Anthralin
Topics
  • Administration, Topical
  • Adult
  • Alopecia Areata (drug therapy)
  • Anthralin (administration & dosage, therapeutic use)
  • Clinical Trials as Topic
  • Female
  • Hair (growth & development)
  • Humans
  • Male
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: